大肠癌原发灶及淋巴结转移灶中TS和Topo-Ⅱ表达的对比分析  

Comparison analysis on expression of TS and Topo-Ⅱ in primary colorectal carcinomas and corresponding lymph-node metastasis tumors by tissue microarray

作　　者：罗枫[1] 吴雪芳[1] 刘坤平[1] 彭辉[2] 李素梅[3] 叶勇[1] 周艳[1] 伍世钢[1] 

机构地区：[1]暨南大学医学院附属清远医院(清远市人民医院)病理科,广东清远511500 [2]广东省中医院病理科,广东广州510120 [3]暨南大学医学院人体解剖学教研室,广东广州510632

出　　处：《热带医学杂志》2012年第10期1178-1180,1236,共4页Journal of Tropical Medicine

基　　金：广东省科技计划项目(2009B080800023)

摘　　要：目的探讨胸苷酸合成酶(TS)和拓扑异构酶II(Topo-Ⅱ)在大肠癌原发灶及淋巴结转移灶的表达及临床意义。方法应用组织芯片及免疫组化技术,检测TS和Topo-II在135例大肠癌和60例淋巴结转移灶的表达情况。结果 TS在135例大肠癌和癌旁正常黏膜组织中的阳性表达率分别为54.81%和42.96%,差异无统计学意义(P>0.05),大肠癌TS表达与各临床病理参数无关(P>0.05),60例大肠癌淋巴结转移灶中TS阳性表达率为41.67%,与原发灶TS阳性表达率(53.33%)比较差异无统计学意义(P>0.05)及无相关性(r=0.045,P=0.732)。Topo-II在135例大肠癌和癌旁正常黏膜组织中的阳性表达率分别为53.33%和21.48%,差异有统计学意义(P<0.05),Topo-Ⅱ阳性表达率与大肠癌组织学分级有关,中分化腺癌高于高分化腺癌(P<0.05),60例大肠癌原发灶中Topo-Ⅱ阳性表达率(56.67%)显著高于淋巴结转移灶(31.67%,P<0.05)且呈正相关(r=0.261,P=0.044)。结论大肠癌原发灶与淋巴结转移灶TS和Topo-Ⅱ蛋白表达存在一定的差异,淋巴结转移灶耐药蛋白表达的检测对术后体内残存肿瘤细胞耐药性评估可能更为客观。Objective To explore the expression and clinical significance of TS and Topo-Ⅱ in colorectal carcinomas and their lymph-node metastasis. Method Tissue microarray technique and immunochemical staining were performed to detect the expression of TS and Topo-Ⅱ protein in 135 colorectal cancer tissues and 60 lymph-node metastasis tumors. Results The positive rate of TS protein expression was 54.81% in 135 colorectal carcinomas tissues,42.96% in 135 peritumor tissues. There was no significant difference between colorectal carcinomas tissues and peritumor tissues（P0.05）. The positive expression of TS protein in colorectal carcinomas tissues was not significantly correlated with clinicopathological features（P0.05）. There was no significant difference for TS expression between 60 primary colorectal carcinomas（53.33%） and the matched lymph-node metastasis（41.67%,P0.05）, the correlation of TS expression between primary colorectal carcinomas and matched lymph-node metastasis was not verified（r=0.045,P=0.732）. The positive rate of Topo-Ⅱ protein expression in 135 colorectal carcinomas tissues（53.33%） was higher than that in peritumor tissues（21.48%, P0.05）. The expression of Topo-Ⅱ in moderately differentiated adenocarcinoma was significantly higher than that in well differentiated adenocarcinoma（P0.05）. The expression of Topo-Ⅱ in 60 primary colorectal carcinomas（56.67%） was significantly higher than that in the matched lymph node metastasis（31.67%, P0.05）. There was a significant correlation for Topo-Ⅱ expression between primary colorectal carcinomas and matched lymph-node metastasis（r=0.261,P=0.044）. Conclusions There were differences in the expression patterns of TS and Topo-Ⅱ between primary colorectal carcinomas and matched lymph-node metastasis. Detection of resistance protein in lymph-node metastasis is considered to be more reliable for assessing the drug resistance of residual tumor cells.

关 键 词：大肠癌 组织芯片 胸苷酸合成酶 拓扑异构酶Ⅱ 淋巴结转移 

分 类 号：R735.34[医药卫生—肿瘤]